1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,460 | 1,490 | 07:00 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | INTELLIGENT BIO SOLUTIONS INC. - 8-K, Current Report | 1 | SEC Filings | ||
| Di | Intelligent Bio Solutions, Inc.: Intelligent Bio Solutions Expects to Report Record Fiscal First Quarter 2026 Revenue of Over $1 Million, an Increase of Approximately 32% Sequentially and 28% Year-Over-Year | 5 | GlobeNewswire (USA) | ||
| 30.10. | INTELLIGENT BIO SOLUTIONS INC. - 8-K, Current Report | 3 | SEC Filings | ||
| 30.10. | Intelligent Bio Solutions, Inc.: Intelligent Bio Solutions Secures 33 New Customer Accounts in the Fiscal 2026 First Quarter, Showing Strong Year-Over-Year Growth and Increasing Total Active Accounts to 480 | 179 | GlobeNewswire (Europe) | NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing... ► Artikel lesen | |
| 23.10. | UK industrial service provider adopts INBS drug testing technology | 2 | Investing.com | ||
| INTELLIGENT BIO SOLUTIONS Aktie jetzt für 0€ handeln | |||||
| 23.10. | Intelligent Bio Solutions, Inc.: Intelligent Bio Solutions Secures Major UK Contract with Multinational Industrial Service Provider | 184 | GlobeNewswire (Europe) | Multinational company employs approximately 3,000 staff within the UK and Ireland and more than 30,000 staff worldwide Large new customer account highlights accelerating adoption of the Company's... ► Artikel lesen | |
| 21.10. | INTELLIGENT BIO SOLUTIONS INC. - 8-K, Current Report | 8 | SEC Filings | ||
| 26.09. | Intelligent Bio Solutions updates FDA 510(k) timeline for drug test | 4 | Investing.com | ||
| 26.09. | Intelligent Bio Solutions, Inc.: Intelligent Bio Solutions Advances Preparations and Provides Updated Timeline for Anticipated FDA 510(k) Submission and Clearance | 212 | GlobeNewswire (Europe) | The Company is initiating clinical studies to further validate Intelligent Fingerprinting Drug Screening System INBS anticipates FDA 510(k) clearance in the second half of 2026 NEW YORK, Sept. 26... ► Artikel lesen | |
| 25.09. | Intelligent Bio Solutions verlängert Laufzeit von Optionsscheinen der Serie H-1 bis März 2026 | 9 | Investing.com Deutsch | ||
| 25.09. | INTELLIGENT BIO SOLUTIONS INC. - 8-K, Current Report | 4 | SEC Filings | ||
| 17.09. | Intelligent Bio Solutions faces FDA request for new 510(k) submission | 4 | Investing.com | ||
| 17.09. | INTELLIGENT BIO SOLUTIONS INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 17.09. | Intelligent Bio Solutions: FDA fordert neuen 510(k)-Antrag für Drogenscreening-System | 4 | Investing.com Deutsch | ||
| 17.09. | Intelligent Bio Solutions, Inc.: Intelligent Bio Solutions Provides Update on FDA 510(k) Clearance Process for Intelligent Fingerprinting Drug Screening System | 164 | GlobeNewswire (Europe) | NEW YORK, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing... ► Artikel lesen | |
| 19.08. | Intelligent Bio Solutions rise on record cartridge sales | 4 | Seeking Alpha | ||
| 19.08. | Intelligent Bio Solutions, Inc.: Intelligent Bio Solutions Achieves Record Monthly Sales of 12,500+ Units of Higher-Margin Cartridges in July | 168 | GlobeNewswire (Europe) | NEW YORK, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing... ► Artikel lesen | |
| 15.08. | INTELLIGENT BIO SOLUTIONS INC. - 8-K, Current Report | 6 | SEC Filings | ||
| 15.08. | Intelligent Bio Solutions GAAP EPS of -$2.00, revenue of $3.05M | 4 | Seeking Alpha | ||
| 15.08. | Intelligent Bio Solutions, Inc.: Intelligent Bio Solutions Reports Fiscal 2025 Fourth Quarter and Full Year Results, Highlighting Progress on Planned U.S. Market Expansion, Revenue Growth and Increased Operational Efficiencies | 242 | GlobeNewswire (Europe) | Company advanced efforts to secure U.S. FDA 510(k) clearance to advance on path towards planned U.S. market expansion beyond Forensic Use Only settings Fourth quarter sequential and year-on-year revenue... ► Artikel lesen |
1 2 3 4 Weiter >>
62 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ECKERT & ZIEGLER | 15,890 | +1,47 % | EQS-PVR: Eckert & Ziegler SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution | EQS Voting Rights Announcement: Eckert & Ziegler SE
Eckert & Ziegler SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective... ► Artikel lesen | |
| DRAEGERWERK | 67,95 | +1,12 % | ANALYSE-FLASH: Jefferies hebt Ziel für Drägerwerk auf 73 Euro - 'Hold' | NEW YORK (dpa-AFX) - Das Analysehaus Jefferies hat das Kursziel für Drägerwerk von 67 auf 73 Euro angehoben und die Einstufung auf "Hold" belassen. Das Medizin- und Sicherheitstechnik-Unternehmen habe... ► Artikel lesen | |
| TELADOC HEALTH | 6,557 | +0,63 % | Teladoc Health, Inc.: Teladoc Health Announces Employee Inducement Award under NYSE Rule 303A.08 | ||
| ROKU | 89,70 | +1,39 % | Cathie Wood's ARK sells Roku, buys Archer Aviation stock | ||
| HIMS & HERS HEALTH | 36,980 | +4,23 % | Zahlen veröffentlicht: Hims & Hers übertrifft Umsatzprognosen: Kommt ein Deal mit Novo Nordisk? | © Foto: Dall-EHims & Hers Health setzt auf Expansion, Diagnostik und einen möglichen Deal mit dem dänischen Pharmariesen Novo Nordisk. Die Aktie steigt nachbörslich deutlich.Das US-amerikanische Telemedizinunternehmen... ► Artikel lesen | |
| BICO GROUP | 1,902 | -1,14 % | BICO Group AB: Publication of BICO Group AB: Interim report Q3 2025 | Organic sales growth in a continued soft market
Q3 2025 SummaryLife Science Solutions showed 4 percent organic sales growth YoY, which is in line with market performance. SCIENION continued to perform... ► Artikel lesen | |
| SERNOVA BIOTHERAPEUTICS | 0,092 | +1,67 % | Sernova Biotherapeutics Announces $13 Million Debt-to-Equity Conversion Eliminating Significant Financing Overhang | Toronto, Ontario and Boston, Massachusetts--(Newsfile Corp. - October 1, 2025) - Sernova Biotherapeutics (TSX: SVA) (OTCQB: SEOVF) (FSE: PSH0) ("Sernova") a leading regenerative medicine company focused... ► Artikel lesen | |
| GERATHERM MEDICAL | 3,640 | -2,67 % | Geratherm Medical AG: Starkes Wachstum im ersten Halbjahr und operatives Break-even; KAUFEN bestätigt. | Geratherm verzeichnete im ersten Halbjahr 2025 ein starkes Wachstum: Die vergleichbaren Umsätze stiegen um 13,2 % gegenüber dem Vorjahr und sequenziell um 15,4 %. Getrieben wurde dieses Wachstum von... ► Artikel lesen | |
| SYNLAB | 12,710 | 0,00 % | EQS-News: SYNLAB AG: Weitere Investitionen in Italien für modernste Diagnostik und Patientenkomfort | EQS-News: SYNLAB
/ Schlagwort(e): Strategische Unternehmensentscheidung
Weitere Investitionen in Italien für modernste Diagnostik und Patientenkomfort
23.10.2025... ► Artikel lesen | |
| ALIGN TECHNOLOGY | 117,60 | +0,86 % | ALIGN TECHNOLOGY INC - 10-Q, Quarterly Report | ||
| NUGEN MEDICAL DEVICES | 0,026 | 0,00 % | NuGen Medical: Kurs explodiert nach wichtiger News! | ||
| PLUS THERAPEUTICS | 0,537 | +4,53 % | Plus Therapeutics Inc.: Plus Therapeutics Highlights ReSPECT-LM Clinical Trial Results at 40th SITC Annual Meeting, Melanoma Research Foundation Brain Metastases Summit 4.0 | ||
| HEALWELL AI | 0,818 | +1,24 % | HEALWELL AI meldet strategische Veräußerungen und den Übergang zu einem reinen SaaS-, Dienstleistungs- und KI-Geschäft | - HEALWELL veräußerte seine Polyclinic Family Medicine and Specialty Clinics Group an WELL Health Clinic Network Inc. ("WELL Clinics"), die diese Kliniken bereits seit Januar 2024 für... ► Artikel lesen | |
| ATOSSA THERAPEUTICS | 0,680 | -3,68 % | Atossa Therapeutics Inc: Atossa Appoints Mark Daniel, CPA, as Chief Financial Officer to Lead Finance, Systems, and Capital Strategy for Commercial Readiness | 25+ year life-sciences finance leader brings revenue-forecasting rigor, public-company controls, and capital-markets experience as Atossa prepares for commercial... ► Artikel lesen | |
| SPINEWAY | 0,150 | -0,13 % | Spineway: Revenue growth in the third quarter | Ecully, October 14, 2025 - 6:30 p.m. SPINEWAYRevenue growth in the third quarter In thousands of euros20252024Change as a %Q3 revenue3,0452,575 +18%Q2 revenue2,7453,465-21% Q1 revenue2,8283,070-8%9M... ► Artikel lesen |
INTELLIGENT BIO SOLUTIONS INC gehört der Branche Gesundheitswesen an. Der aktuelle Kurs liegt bei 1,475 Euro und damit -100,00 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INTELLIGENT BIO SOLUTIONS INC finden Sie auf Wallstreet Online.